- Home
- PMM vs FDMT Comparison
PMM vs FDMT Comparison
Compare PMM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | FDMT |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.4M | 695.3M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PMM | FDMT |
|---|---|---|
| Price | $5.82 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 75.8K | ★ 896.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.28 |
| P/E Ratio | $27.43 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $5.91 | $6.47 |
| 52 Week High | $6.60 | $16.93 |
Technical Indicators
Market Signals| Indicator | PMM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 16.46 | 49.22 |
| Support Level | N/A | $8.43 |
| Resistance Level | $6.35 | $14.00 |
| Average True Range (ATR) | 0.07 | 0.83 |
| MACD | -0.03 | -0.30 |
| Stochastic Oscillator | 7.55 | 24.38 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).